VXA-CoV2-1.1-S for COVID-19

"Currently, AMR Wichita East in Wichita, Velocity Clinical Research Inc. in Cleveland and AMR Knoxville in Knoxville are amongst the four sites actively recruiting for this study. Additionally, there is availability at other locations as well."

"VXA-CoV2-1.1-S was first studied in 2021, with the opening study funded by Vaxart and involving 896 participants. After completing its Phase 2 drug approval stage that year, today there is only one active trial for this medication which is being sponsored again by Vaxart."

"VXA-CoV2-1.1-S was first researched at Ark Clinical Research in 2021, with 16 trials having been completed. The current studies are centred around Wichita, Kansas and there is one still active trial."

"To be admitted to this clinical study, the participant must have been infected with covid-19 and they must fall between 18 - 75 years. This trial is set to include 896 people in total."

"This research study is open to individuals over the age of majority and below 75 years old."

"This research trial, which is estimated to take up to 36 days, aims to evaluate the incidence of unsolicited adverse events. Additionally, four weeks post second immunization (Day 57), Mesoscale Discovery assays will be used to assess changes in SARS-CoV2 specific Immunoglobulin G and A antibodies from baseline levels at Day 29."

"To ensure the successful completion of this clinical trial, 896 participants must be recruited who meet all specified inclusion criteria. Vaxart will run the study from two sites: AMR Wichita East in Kansas and Velocity Clinical Research Inc. located in Ohio."

"The information displayed on clinicaltrials.gov verifies that this medical trial is actively looking for participants, and was originally published on October 1st 2021 before being revised as recently as September 19th 2022."

"Given the Phase 2 trial status of VXA-CoV2-1.1-S, Power assigned it a safety ranking of 2 due to some data indicating its security but none demonstrating effectiveness."